comscoreNoticias de investigación

Noticias de investigación

Descubre qué significan para ti los resultados de los estudios clínicos más recientes.
Más sobre este tema
1389 Noticias de investigación
¿Un nuevo estándar de atención? Enhertu mejora la supervivencia de personas con cáncer de mama metastásico con niveles bajos de HER2

En comparación con el tratamiento quimioterapéutico elegido por el médico, Enhertu (nombre genérico: fam-trastuzumab deruxtecan-nxki) mejoró tanto la supervivencia sin progresión y la supervivencia en general en personas diagnosticadas con cáncer de mama metastásico con niveles bajos de HER2 que habían recibido tratamiento anteriormente.

FDA Approves Enhertu for Unresectable or Metastatic HER2-Low Breast Cancer

On Aug. 5, 2022, the U.S. Food and Drug Administration approved Enhertu to treat unresectable or metastatic HER2-low breast cancer.

FDA Approves Immunotherapy Keytruda for PD-L1-Positive Triple-Negative Breast Cancer

On Nov. 13, 2020, the FDA approved the immunotherapy Keytruda in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer.

Metformin Seems to Lower Risk of Estrogen-Receptor-Positive Breast Cancer in Women With Type 2 Diabetes

Women with type 2 diabetes who take metformin to control their blood sugar appear to have a lower risk of estrogen-receptor-positive breast cancer.

8 feb 2021 | Factores de riesgo
First Screening Mammography Guidelines for Older Breast Cancer Survivors Recommend Individualized Approach

The first screening mammography guidelines for breast cancer survivors age 75 and older encourage people and their doctors to come to a decision that is individualized for each person after discussing the benefits and risk of screening mammograms, as well as the person's preferences.

Scalp Cooling Reduces Hair Loss by Lessening Chemotherapy Absorbed by Hair Follicles

A study offers a first peek at the biology behind scalp cooling by finding that scalp cooling dramatically reduces the amount of chemotherapy medicine absorbed by the hair follicles.

16 feb 2021 | Quimioterapia
Oncotype DX Results Appear Less Accurate in Black Women Diagnosed With Certain Early-Stage Breast Cancers

Black women diagnosed with stage I to stage III estrogen-receptor-positive, axillary node-negative breast cancer were more likely to die from breast cancer than white women with similar diagnoses and similar Oncotype DX Breast Recurrence Scores.

Adding Surgery to Standard Treatments Linked to Better Survival for Certain Types of Metastatic Breast Cancer

Having surgery along with systemic treatments or with systemic treatments and radiation therapy can improve survival for women diagnosed with metastatic hormone-receptor-positive or HER2-positive breast cancer.

Most Women Satisfied With Choice to Go Flat After Mastectomy, but Choice Not Supported by Many Surgeons

Nearly 75% of women surveyed who opted for mastectomy without reconstruction were satisfied with the results, but almost 25% said their decision to go flat was not supported by their surgeons.

New Tool Helps Predict Risk of Severe Chemotherapy Side Effects in Older People With Early-Stage Breast Cancer

By combining eight factors, a new tool called the Cancer and Aging Research Group-Breast Cancer score helps predict whether older people diagnosed with early-stage breast cancer will have serious side effects from chemotherapy.

20 ene 2021 | Diagnóstico y Quimioterapia
Exercise Plus Mindfulness Training May Ease Fatigue in Breast Cancer Survivors, Small Study Suggests

A combination of exercise and mindfulness training seems better at easing fatigue in breast cancer survivors than either technique alone, according to a small study.

Some Older Women With Early-Stage Hormone-Receptor-Positive, Node-Positive Breast Cancer Can Skip Chemotherapy

Postmenopausal women diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer with one to three positive lymph nodes and an Oncotype DX Recurrence Score of 25 or lower being treated with hormonal therapy after surgery can safely skip chemotherapy.

Following Diet Plan to Reduce Diabetes Risk Means Better Survival for Women With Early-Stage Breast Cancer

Women diagnosed with stage I to stage III breast cancer who more closely followed a diet designed to reduce the risk of diabetes had better survival than women who didn't follow the diet as strictly.

Mindfulness Meditation, Survivorship Classes Ease Depression in Younger Women Treated for Breast Cancer

Mindfulness meditation and survivorship education classes eased symptoms of depression in younger women treated for breast cancer.

Doctors May Not Recognize Severity of Radiation Side Effects in Certain Breast Cancer Patients

It's common for doctors to fail to understand the severity of radiation therapy side effects in women treated with radiation after lumpectomy, especially younger women and Black women.

Most Women Treated for Breast Cancer Take Dietary Supplements, Many Not Aware of Interactions With Hormonal Therapy

Up to 80% of women treated for breast cancer take at least one dietary supplement, but many women are not aware that the supplements they're taking may interact with hormonal therapy medicines.

21 dic 2020 | Diagnóstico y Nutrición
FDA Approves Margenza Plus Chemotherapy for Pretreated Metastatic HER2-Positive Breast Cancer

On Dec. 16, 2020, the FDA approved the targeted therapy Margenza in combination with chemotherapy to treat people diagnosed with metastatic HER2-positive breast cancer who have been treated previously with two or more anti-HER2 regimens, at least one of which was for metastatic disease.

Pregnancy Is Safe After a Breast Cancer Diagnosis, Study Shows

Women who have been treated for breast cancer are less likely than the average woman to get pregnant and have a higher risk of certain complications, such as preterm labor, but most deliver healthy babies and childbirth has no effect on their long-term survival.

Some Older Women With Early-Stage Hormone-Receptor-Positive Breast Cancer May Be Able to Skip Radiation After Lumpectomy

Some women age 65 and older diagnosed with early-stage hormone-receptor-positive breast cancer with a low risk of the cancer coming back who have lumpectomy followed by hormonal therapy treatment may be able to skip radiation therapy after surgery.

22 dic 2020 | Diagnóstico y Radioterapia
Does Taking Beta Blockers Affect HER2-Positive Breast Cancer Survival?

There may be a link between taking beta blockers, a heart medicine, before being diagnosed with advanced-stage HER2-positive breast cancer and worse survival after being treated with anti-HER2 medicines.

Can Some Older Women With Early-Stage HER2-Positive Breast Cancer Skip Chemotherapy?

Certain woman age 70 to 80 may be able to skip chemotherapy after surgery for early-stage HER2-positive disease and be treated with Herceptin alone.

Pathologic Complete Response to Targeted Therapy Before Surgery Linked to Better Survival for Early-Stage HER2-Positive Breast Cancer

Women diagnosed with early-stage HER2-positive breast cancer treated with Herceptin and Tykerb before surgery who had a pathologic complete response (pCR) had better survival than women who didn't have a pCR.

Early Results Suggest Ibrance Plus Faslodex as First Treatment Improves Outcomes for Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer

Adding Ibrance to Faslodex as a first treatment for advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that either came back (recurred) more than 1 year after completing 5 or more years of hormonal therapy or was metastatic at first diagnosis improved progression-free survival compared to Faslodex alone.

Trodelvy Improves Outcomes for Previously Treated Metastatic Triple-Negative Breast Cancer

Compared to standard chemotherapy, Trodelvy offered better outcomes for people diagnosed with previously treated metastatic triple-negative breast cancer.

Se muestran 24 de 1389